Roquefort Therapeutics (LON:ROQ) Trading 3.2% Higher – Still a Buy?

Roquefort Therapeutics plc (LON:ROQ) rose 3.2% on Thursday . The stock traded as high as GBX 0.98 and last traded at GBX 0.98. Approximately 439,612 shares were traded during trading, a decline of 54% from the average daily volume of 953,795 shares. The stock had previously closed at GBX 0.95.

Roquefort Therapeutics Trading Down 7.1%

The company has a current ratio of 2.80, a quick ratio of 3.07 and a debt-to-equity ratio of 8.07. The business has a 50 day simple moving average of GBX 1.19 and a 200-day simple moving average of GBX 1.55. The stock has a market capitalization of £1.60 million, a price-to-earnings ratio of -1.55 and a beta of 0.05.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.